Price
No data yet.
Social Signal Score
Revenue
$570.58B+162.89%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Hiroyuki Okuzawa
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 20,171
- Beta
- 0.12
- Country
- JP
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.96
Financials
Revenue
$570.58B+162.9%Net Income
$68.14B+270.6%EBITDA
$105.75B+179.1%Free Cash Flow
$-16.78B-174.8%EPS (diluted)
$37.13+309.8%Shares Outstanding (diluted)
1.82B-10.3%Operating Expenses
$362.77BCash & Debt
$633.24BReturn of Capital
$70.71BDividend per Share
$0.31Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $2.14T | $261.51B | $140.61 |
| 2025 | $1.89T | $295.76B | $155.96 |
| 2024 | $1.60T | $200.73B | $104.69 |
| 2023 | $1.28T | $109.19B | $56.96 |
| 2022 | $1.04T | $66.97B | $34.94 |
| 2021 | $962.52B | $75.96B | $39.17 |
| 2020 | $981.79B | $129.07B | $66.40 |
| 2019 | $929.72B | $93.41B | $48.07 |
| 2018 | $960.20B | $60.28B | $30.44 |
| 2017 | $955.12B | $53.47B | $26.54 |
| 2016 | $986.45B | $82.28B | $39.79 |
| 2015 | $919.37B | $322.12B | $152.52 |
| 2014 | $899.13B | $60.94B | $28.86 |
| 2013 | $994.66B | $64.03B | $30.32 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DSKYF's reported EPS growth of 12.5% a year over 13 years.
- EPS in 5 years
- $254.67
- Implied price
- $5,348
- Return from $18.00
- 212.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $2,659 — today's price is already 99.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| 2.5% | 166.0% | 175.9% | 184.5% | 192.3% | 199.2% |
| 7.5% | 179.0% | 189.4% | 198.4% | 206.5% | 213.8% |
| 12.5% | 192.0% | 202.8% | 212.3% | 220.8% | 228.4% |
| 17.5% | 205.0% | 216.3% | 226.2% | 235.0% | 243.0% |
| 22.5% | 217.9% | 229.7% | 240.1% | 249.3% | 257.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsbusinesswire.com·6h ago·Neutral
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization.
View source ↗
Earnings
Fri, Oct 30(in 2 months)
Consensus estimate $0.25 per share
Typical surprise +5.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Jul 31$0.23 vs $0.25miss
- Mon, May 11$0.15 vs $0.33miss
- Fri, Jan 30$0.30 vs $0.25beat
- Fri, Oct 31$0.17 vs $0.30miss
- Thu, Jul 31$0.32 vs $0.24beat
- Fri, Apr 25$0.31 vs $0.13beat
Estimates and results for DSKYF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.